FORTEO and Bone Formation

Some medicines can slow or stop bone loss, but only FORTEO® (teriparatide [rDNA origin] injection) can rebuild bone.1,2

Osteoporosis makes bones more susceptible to fracture, which can sometimes go undetected. Common signs of fracture include height loss, kyphosis, and acute back pain. This site will help you find out more about FORTEO and how it reduces fracture risk, rapidly increases BMD and rebuilds bone.

FORTEO is an anabolic agent which acts differently than other therapies. Below, you can see a rapid and sustained increase in P1NP (a bone formation marker) consistent with an anabolic effect on the bone. Products that treat osteoporosis work through different mechanisms of action. Fosamax® treatment results in a rapid decrease in markers of bone resorption and bone formation, consistent with an overall decrease in bone turnover. Information regarding mechanisms of action does not provide evidence of comparative fracture protection.

Changes in bone turnover markers with FORTEO compared to Fosamax*†3,4
  1. National Osteoporosis Foundation: Medications To Prevent & Treat Osteoporosis. http://www.nof.org/patientinfo/medications.htm. Accessed April 15th, 2007.
  2. N Engl J Med 2001;344:1434-1441.
  3. Archives of Internal Medicine 2005;165:1762-1768.
  4. Data on File. Lilly Research Laboratories (FOR20061205A).

*As measured by the surrogate marker P1NP.
†Information regarding mechanisms of action does not provide evidence of comparative fracture protection.
‡Percentage change from baseline (mean SE).
Fosamax is a registered trademark of Merck & Co., Inc.

FORTEO® (teriparatide [rDNA origin] injection) is indicated

  • For the treatment of postmenopausal women with osteoporosis at high risk for fracture.
  • To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture.
  • For the treatment of men and women with osteoporosis associated with sustained, systemic glucocorticoid therapy at high risk for fracture.